Goldman Sachs
MRSN

Goldman Sachs’s Mersana Therapeutics MRSN Stock Holding History

Goldman Sachs’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-800
Closed -$468K – 5469
2020
Q2 		$468K Buy
+800
New +$273K ﹤0.01% 4413

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's MRSN Position: Q3 2025 in Review

Goldman Sachs sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 57,350 shares — an estimated $424K sold.

Goldman Sachs first reported a position in MRSN in Q2 2017 and held it in 32 quarters. The position peaked at $27.7M in Q4 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Goldman Sachs reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 57,350 Mersana Therapeutics shares in Q3 2025, an estimated $424K.
  • Goldman Sachs first reported a position in Mersana Therapeutics in Q2 2017 and held it in 32 quarters.
  • Goldman Sachs's Mersana Therapeutics position peaked at $27.7M in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.